The Senate has advanced the U.S. Food and Drug Administration’s (FDA) Reauthorization Act, which expands four separate user fee agreements on new drugs, generic drugs, medical devices, and biosimilars, and includes a provision to maximize the development of therapies for children with cancer.
The U.S. Food and Drug Administration announced today a new, comprehensive approach to confront nicotine addiction in the U.S. through the agency’s authority over tobacco products.
The U.S. Senate is reported to be considering a “skinny” health care repeal bill that according to earlier Congressional Budget Office estimates of similar repeal could cause 15 million Americans to lose their insurance coverage over the next ten years
A new report shows that while opportunities for coverage have improved, cancer patients still struggle with significant financial challenges in affording their treatment despite substantial reductions in out-of-pocket costs and patient protections under current law.
Six leading public health organizations today asked federal courts to allow them to intervene in two lawsuits brought by the electronic cigarette and cigar industries against the Food and Drug Administration’s 2016 rule establishing public health oversight of e-cigarettes, cigars and other previously unregulated tobacco products
The House Labor, Health and Human Services and Education Committee marked up its FY 2018 spending bill today including a $1.1 billion funding increase for the National Institutes of Health (NIH) and a $82 million funding boost for the National Cancer Institute (NCI).
Unlike the House version of this bill, senators did not exempt from FDA oversight many cigars, including some cheap and flavored cigars often popular with youth. The Committee’s action preserves FDA authority to regulate all tobacco products as granted by Congress
Any attempt to repeal the ACA without replacing it with equal or better coverage will leave our health care system in shambles. If the existing law is abolished, 32 million Americans could lose their insurance coverage in the next decade. This approach is completely unacceptable for the patients we represent.
The U.S. House Appropriations Committee approved a bill today that would greatly weaken the Food and Drug Administration’s (FDA) oversight of tobacco products. The provision was included in the FY 2018 Agriculture, Rural Development, Food and Drug Administration (FDA), and Related Agencies appropriations bill.
The House advanced legislation to reauthorize and expand the FDA's user fee programs that maintain a strong partnership between the FDA and industry, with the goal of bringing pharmaceutical drugs and devices to the market, and making them accessible to patients, as expeditiously as possible.